Construction and validation of a prognostic model for predicting overall survival of primary adrenal malignant tumor patients: A population-based study with 1,080 patients
- PMID: 36353609
- PMCID: PMC9637840
- DOI: 10.3389/fsurg.2022.1025213
Construction and validation of a prognostic model for predicting overall survival of primary adrenal malignant tumor patients: A population-based study with 1,080 patients
Abstract
Objective: Primary adrenal malignant tumor is rare. The factors affecting the prognosis remain poorly defined. This study targeted to construct and corroborate a model for predicting the overall survival of adrenal malignant tumor patients.
Methods: We investigated the SEER database for patients with primary adrenal malignant tumor. 1,080 patients were divided into a construction cohort (n = 756) and a validation cohort (n = 324), randomly. The prognostic factors for overall survival were evaluated using univariate and multivariate Cox analyses. The nomogram was constructed and then validated with C-index, calibration curve, time-dependent ROC curve, and decision curve analysis in both cohorts. Then we divided the patients into 3 different risk groups according to the total points of the nomogram and analyzed their survival status by Kaplan-Meier curve with log-rank test.
Results: The baseline characteristics of these two cohorts were not statistically different (P > 0.05). Using univariate and multivariate Cox analyses, 5 variables, including age, tumor size, histological type, tumor stage, and surgery of primary site, were distinguished as prognostic factors (P < 0.05). Based on these variables, we constructed a nomogram to predict the 3- year, 5- year, and 10-year overall survival. The C-indexes were 0.780 (0.760-0.800) in the construction cohort and 0.780 (0.751-0.809) in the validation cohort. In both cohorts, the AUC reached a fairly high level at all time points. The internal and external calibration curves and ROC analysis showed outstanding accuracy and discrimination. The decision curves indicated excellent clinical usefulness. The best cut-off values for the total points of the nomogram were 165.4 and 243.1, and the prognosis was significantly different for the three different risk groups (P < 0.001).
Conclusion: We successfully constructed a model to predict the overall survival of primary adrenal malignant tumor patients. This model was validated to perform brilliantly internally and externally, which can assist us in individualized clinical management.
Keywords: SEER; adrenal malignant tumor; construct; decision curve; nomogram; overall survival; prognosis; validate.
© 2022 Xie, Zhang and Cao.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures






Similar articles
-
Construction of a novel clinical nomogram to predict cancer-specific survival in patients with primary malignant adrenal tumors: a large population-based retrospective study.Front Med (Lausanne). 2023 May 25;10:1184607. doi: 10.3389/fmed.2023.1184607. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37305122 Free PMC article.
-
Establishment and validation of an individualized nomogram for survival prediction of primary mediastinal germ cell tumors based on the SEER database.Ann Transl Med. 2022 Sep;10(18):988. doi: 10.21037/atm-22-4181. Ann Transl Med. 2022. PMID: 36267730 Free PMC article.
-
Identification of prognostic factors for predicting survival of patients with malignant adrenal tumors: A population-based study.Front Oncol. 2022 Oct 17;12:930473. doi: 10.3389/fonc.2022.930473. eCollection 2022. Front Oncol. 2022. PMID: 36324596 Free PMC article.
-
Development and validation of a prognostic nomogram for predicting overall survival in patients with primary bladder sarcoma: a SEER-based retrospective study.BMC Urol. 2021 Nov 25;21(1):162. doi: 10.1186/s12894-021-00929-x. BMC Urol. 2021. PMID: 34823525 Free PMC article.
-
Development and validation of a nomogram model for cancer-specific survival of patients with poorly differentiated thyroid carcinoma: A SEER database analysis.Front Endocrinol (Lausanne). 2022 Sep 13;13:882279. doi: 10.3389/fendo.2022.882279. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36176465 Free PMC article. Clinical Trial.
Cited by
-
Construction of a novel clinical nomogram to predict cancer-specific survival in patients with primary malignant adrenal tumors: a large population-based retrospective study.Front Med (Lausanne). 2023 May 25;10:1184607. doi: 10.3389/fmed.2023.1184607. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37305122 Free PMC article.
-
Estimation of the tumor size at cure threshold among adult patients with adrenocortical carcinoma: A populational-based study.Heliyon. 2024 Mar 22;10(7):e28160. doi: 10.1016/j.heliyon.2024.e28160. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38571632 Free PMC article.
References
-
- Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: esmo-euracan clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2020) 31(11):1476–90. 10.1016/j.annonc.2020.08.2099 - DOI - PubMed
-
- Mege D, Taieb D, Lowery A, Loundou A, Micco CDE, Castinetti F, et al. Contemporary review of large adrenal tumors in a tertiary referral center. Anticancer Res. (2014) 34(5):2581–8. - PubMed
LinkOut - more resources
Full Text Sources